Earnings call transcript: Carl Zeiss Meditec Q2 2026 highlights adjusted EPS beat

Carl Zeiss Meditec reported H1 revenue of EUR 991 million, down 5.7% year over year, while adjusted EPS of EUR 0.48 beat expectations and pre-market shares rose 0.58%. Management guided FY 2025/26 revenue to EUR 2.15 billion-EUR 2.2 billion and adjusted EBITDA margin of 8%-10%, but flagged currency headwinds, China IOL disruption, and up to EUR 150 million of restructuring-related one-offs. The company also outlined a major Profit Up program targeting more than EUR 200 million of annual profit improvement by FY 2028/29, alongside product launches including VISUMAX 800 and SMILE Pro expansion.

Analysis

The key signal is not the near-term earnings beat; it is management’s implicit admission that the old operating model no longer scales in a slower, more regionalized demand environment. The announced restructuring is effectively a margin reset, but the path is back-end loaded and depends on execution across procurement, footprint, and commercial productivity before the revenue base has fully stabilized. That makes the next two quarters more about cash preservation and mix repair than about clean earnings momentum.

The second-order issue is China: the company is trying to protect premium pricing while simultaneously facing tender timing slippage, competitive encroachment, and product relisting risk in IOLs. Even if procedure volumes remain constructive, the mix shift toward lower-priced or delayed products can cap operating leverage just as the company is counting on a second-half rebound. This creates a setup where headline revenue can inflect while margin recovery lags, which is the opposite of what the market usually wants to see in a turnaround.

Competitively, this is favorable for more focused ophthalmology platforms and for suppliers that are not as exposed to China tender resets or legacy portfolio drag. The hidden winner may be firms with cleaner exposure to refractive procedure growth and less baggage from restructuring, because customers will increasingly favor vendors that can combine workflow breadth with local execution. The contrarian read is that the market may be underestimating how much of the 2028-29 profit bridge is already spoken for by higher infrastructure costs and one-offs, leaving less “real” upside than the gross savings headline suggests.

Key Decisions for Investors

• Short AFXG / long a cleaner med-tech peer basket for 3-6 months: the setup is vulnerable to margin disappointment if China tender timing slips again or if second-half recovery proves more mix-driven than volume-driven.
• Buy 6-9 month put spreads on AFXG around the next catalyst window (China VBP / restructuring detail updates): the risk/reward favors a downside convexity trade because guidance already embeds meaningful caution and execution risk is high.
• If you want to express the competitive winner angle, go long selected ophthalmic peers with less China IOL exposure on any pullback over the next 1-2 months; the relative thesis is that capital will rotate toward simpler growth stories with cleaner margins.
• Avoid chasing the bounce in the next few sessions; wait for either confirmation that Q3 exits at positive organic growth or for a weaker read-through on China refractive pricing before taking long exposure.
• For event-driven books, pair a long in a high-quality med-tech name with a short AFXG position into the next earnings cycle to isolate restructuring-execution risk from broader sector beta.